Finally, the epigenetic and metabolic vulnerabilities in the neuroblastoma and small cell lung cancer cell lines serving as representative NENs were evident in the drug–drug combination analysis where the combination of HDAC and NAMPT inhibitors demonstrated synergy even when both agents were combined at low sub-lethal concentrations. The gene discussed is HDAC9; the disease is neuroblastoma.